These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 11474662)

  • 1. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
    Ellis CN; Krueger GG;
    N Engl J Med; 2001 Jul; 345(4):248-55. PubMed ID: 11474662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
    Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
    Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.
    Gordon KB; Vaishnaw AK; O'Gorman J; Haney J; Menter A;
    Arch Dermatol; 2003 Dec; 139(12):1563-70. PubMed ID: 14676071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis.
    Ortonne JP; Lebwohl M; Em Griffiths C;
    Eur J Dermatol; 2003; 13(2):117-23. PubMed ID: 12695125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis.
    Langewouters AM; Bovenschen HJ; De jong EM; Van Erp PE; Van De Kerkhof PC
    J Dermatolog Treat; 2007; 18(5):279-85. PubMed ID: 17852631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept.
    Larsen R; Ryder LP; Svejgaard A; Gniadecki R
    Clin Exp Immunol; 2007 Jul; 149(1):23-30. PubMed ID: 17403057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting T-cell subsets to achieve remission.
    Christophers E
    J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():6-11. PubMed ID: 12795769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis.
    Ortonne JP
    J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():12-6. PubMed ID: 12795770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
    Ortonne JP; Khemis A; Koo JY; Choi J
    J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):556-63. PubMed ID: 16164708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical update on alefacept: consideration for use in patients with psoriasis.
    Gade JN
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S33-7. PubMed ID: 15253688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis.
    Kraan MC; van Kuijk AW; Dinant HJ; Goedkoop AY; Smeets TJ; de Rie MA; Dijkmans BA; Vaishnaw AK; Bos JD; Tak PP
    Arthritis Rheum; 2002 Oct; 46(10):2776-84. PubMed ID: 12384938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.
    Bovenschen HJ; Gerritsen WJ; van Rens DW; Seyger MM; de Jong EM; van de Kerkhof PC
    Arch Dermatol Res; 2007 Feb; 298(9):457-63. PubMed ID: 17136563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and use of alefacept to treat psoriasis.
    Krueger GG; Callis KP
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S87-97. PubMed ID: 12894131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of alefacept in the treatment of psoriasis.
    Wong VK; Lebwohl M
    Skin Therapy Lett; 2003 Sep; 8(6):1-2, 7. PubMed ID: 14610613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
    Chamian F; Lin SL; Lee E; Kikuchi T; Gilleaudeau P; Sullivan-Whalen M; Cardinale I; Khatcherian A; Novitskaya I; Wittkowski KM; Krueger JG; Lowes MA
    J Transl Med; 2007 Jun; 5():27. PubMed ID: 17555598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possibilities of using alefacept in the treatment of psoriasis.
    Pietrzak A; Chodorowska G; Bartkowiak-Emeryk M; Pietrzak B; Urban J; Juszkiewicz-Borowiec M; Miturska R
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):311-3. PubMed ID: 15323211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis.
    Goedkoop AY; de Rie MA; Picavet DI; Kraan MC; Dinant HJ; van Kuijk AW; Tak PP; Bos JD; Teunissen MB
    Arch Dermatol Res; 2004 Apr; 295(11):465-73. PubMed ID: 14968366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.
    Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF
    J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis.
    Ortonne JP; Prinz JC
    Eur J Dermatol; 2004; 14(1):41-5. PubMed ID: 14965795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.
    Scheinfeld N
    J Dermatolog Treat; 2007; 18(4):197-208. PubMed ID: 17671880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.